C07H 17/02
Heterocyclic radicals containing only nitrogen as ring hetero atoms
C07H17/02 (Heterocyclic radicals containing only nitrogen as ring hetero atoms) appears on 415 US grants and 422 published applications in this corpus.
Search patents in C07H- Granted patents
- 415
- Published applications
- 422
- Assignees
- 272
- Inventors
- 1,355
- Latest grant
- 30 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 8 | 0 |
| 1980 | 4 | 0 |
| 1981 | 1 | 0 |
| 1982 | 4 | 0 |
| 1983 | 2 | 0 |
| 1984 | 2 | 0 |
| 1985 | 2 | 0 |
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 2 | 0 |
| 1989 | 7 | 0 |
| 1990 | 4 | 0 |
| 1991 | 3 | 0 |
| 1992 | 3 | 0 |
| 1993 | 4 | 0 |
| 1994 | 7 | 0 |
| 1995 | 11 | 0 |
| 1996 | 11 | 0 |
| 1997 | 4 | 0 |
| 1998 | 7 | 0 |
| 1999 | 5 | 0 |
| 2000 | 5 | 0 |
| 2001 | 4 | 1 |
| 2002 | 2 | 4 |
| 2003 | 10 | 7 |
| 2004 | 4 | 18 |
| 2005 | 5 | 15 |
| 2006 | 10 | 30 |
| 2007 | 9 | 18 |
| 2008 | 10 | 15 |
| 2009 | 11 | 17 |
| 2010 | 12 | 18 |
| 2011 | 14 | 16 |
| 2012 | 6 | 10 |
| 2013 | 20 | 23 |
| 2014 | 30 | 42 |
| 2015 | 20 | 20 |
| 2016 | 23 | 18 |
| 2017 | 14 | 10 |
| 2018 | 10 | 16 |
| 2019 | 15 | 11 |
| 2020 | 14 | 14 |
| 2021 | 11 | 14 |
| 2022 | 9 | 19 |
| 2023 | 16 | 16 |
| 2024 | 14 | 25 |
| 2025 | 14 | 16 |
| 2026 | 7 | 9 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- ASGPR-binding compounds for the degradation of extracellular proteins30 Jun 2026US 12,667,620 B2Avilar Therapeutics, Inc.
- 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD)23 Jun 2026US 12,662,471 B2Vertex Pharmaceuticals Incorporated
- Solid forms of a nucleoside analogue and uses thereof16 Jun 2026US 12,655,172 B2Gilead Sciences, Inc.
- ASGPR-binding compounds for the degradation of extracellular proteins12 May 2026US 12,622,972 B2Avilar Therapeutics, Inc.
- Compound comprising self-immolative group and ligand-drug conjugate comprising same17 Mar 2026US 12,576,156 B2Trioar, Inc.
- Novel linker compound and ligand-drug conjugate therefor27 Aug 2026US 2026/0248936 A1Trioar, Inc.
- Degrader compounds of qsox1 mrna27 Aug 2026US 2026/0250738 A9University of Florida Research Foundation, Inc.
- Modified rna compositions and related methods6 Aug 2026US 2026/0224605 A1Boyce Thompson Institute for Plant Research, Inc.
- Quinoline derivative compounds or pharmaceutically acceptable salt thereof, preparation method therefor and use thereof30 Jul 2026US 2026/0216180 A1Jiangsu Carephar Pharmaceutical Co., Ltd.
- Quinoline derivatives for use in the treatment of inflammation diseases21 May 2026US 2026/0137709 A1Abivax
Most cited
By later US patents
- Bis-modified bicyclic nucleic acid analogs253US 7,666,854 B2Isis Pharmaceuticals, Inc. · 2010
- Nucleoside phosphoramidate prodrugs165US 7,964,580 B2Pharmasset, Inc. · 2011
- Chromogenic acridinone enzyme substrates137US 4,810,636 AMiles Inc. · 1989
- Bis-modified bicyclic nucleic acid analogs125US 8,088,746 B2Isis Pharmaceuticals, Inc. · 2012
- Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile115US 8,486,902 B2Incyte Corporation · 2013